Cecilia Palma, Stefano Piazza, Roberta Visone, Rune Ringom, Ulf Björklund, Antonio Bermejo Gómez, Marco Rasponi, Paola Occhetta
Current treatments for osteoarthritis (OA) often fail to address the underlying pathophysiology and may have systemic side effects, particularly associated with long-term use of non-steroidal anti-inflammatory drugs (NSAIDs). Thus, researchers are currently directing their efforts toward innovative polymer-drug combinations, such as mixtures of hyaluronic acid viscoelastic hydrogels and NSAIDs like diclofenac, to ensure sustained release of the NSAID within the joint following intra-articular injection. However, the progress of novel injectable therapies for OA is hindered by the absence of preclinical models that accurately represent the pathology of the disease. The uBeat® MultiCompress platform is here presented as a novel approach for studying anti-OA injectable therapeutics on human mechanically-damaged OA cartilage microtissues, in a physiologically relevant environment. This platform can accommodate injectable therapeutic formulations and is successfully tested with SYN321, a novel diclofenac-sodium hyaluronate conjugate under development as a treatment for knee OA. Results indicate the platform's effectiveness in evaluating therapeutic potential, showing downregulation of inflammatory markers and reduction in matrix degradation in OA cartilage micro-tissues treated with SYN321. The uBeat® MultiCompress platform thus represents a valuable tool for OA research, offering a bridge between traditional in vitro studies and potential clinical applications, with implications for future drug discovery.
目前治疗骨关节炎(OA)的方法往往不能从根本上解决病理生理学问题,而且可能会产生全身副作用,特别是与长期使用非甾体抗炎药(NSAIDs)有关。因此,研究人员目前正努力开发创新的聚合物药物组合,如透明质酸粘弹性水凝胶和双氯芬酸等非甾体抗炎药的混合物,以确保关节内注射后非甾体抗炎药在关节内的持续释放。然而,由于缺乏能准确反映 OA 病理的临床前模型,新型 OA 注射疗法的发展受到了阻碍。本文介绍的 uBeat® MultiCompress 平台是一种在生理相关环境中研究人体机械损伤 OA 软骨微组织的抗 OA 注射疗法的新方法。该平台可容纳注射治疗制剂,并用 SYN321 成功进行了测试,SYN321 是一种新型双氯芬酸-透明质酸钠共轭物,正在开发用于治疗膝关节 OA。结果表明,该平台在评估治疗潜力方面非常有效,在使用 SYN321 治疗的 OA 软骨微组织中,炎症标志物下调,基质降解减少。因此,uBeat® MultiCompress 平台是研究 OA 的重要工具,它在传统的体外研究和潜在的临床应用之间架起了一座桥梁,对未来的药物研发具有重要意义。
{"title":"An Advanced Mechanically Active Osteoarthritis-on-Chip Model to Test Injectable Therapeutic Formulations: The SYN321 Case Study.","authors":"Cecilia Palma, Stefano Piazza, Roberta Visone, Rune Ringom, Ulf Björklund, Antonio Bermejo Gómez, Marco Rasponi, Paola Occhetta","doi":"10.1002/adhm.202401187","DOIUrl":"https://doi.org/10.1002/adhm.202401187","url":null,"abstract":"<p><p>Current treatments for osteoarthritis (OA) often fail to address the underlying pathophysiology and may have systemic side effects, particularly associated with long-term use of non-steroidal anti-inflammatory drugs (NSAIDs). Thus, researchers are currently directing their efforts toward innovative polymer-drug combinations, such as mixtures of hyaluronic acid viscoelastic hydrogels and NSAIDs like diclofenac, to ensure sustained release of the NSAID within the joint following intra-articular injection. However, the progress of novel injectable therapies for OA is hindered by the absence of preclinical models that accurately represent the pathology of the disease. The uBeat® MultiCompress platform is here presented as a novel approach for studying anti-OA injectable therapeutics on human mechanically-damaged OA cartilage microtissues, in a physiologically relevant environment. This platform can accommodate injectable therapeutic formulations and is successfully tested with SYN321, a novel diclofenac-sodium hyaluronate conjugate under development as a treatment for knee OA. Results indicate the platform's effectiveness in evaluating therapeutic potential, showing downregulation of inflammatory markers and reduction in matrix degradation in OA cartilage micro-tissues treated with SYN321. The uBeat® MultiCompress platform thus represents a valuable tool for OA research, offering a bridge between traditional in vitro studies and potential clinical applications, with implications for future drug discovery.</p>","PeriodicalId":113,"journal":{"name":"Advanced Healthcare Materials","volume":null,"pages":null},"PeriodicalIF":10.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142337574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Implantable neural interfaces can be used to (re-)establish the connection between new (transplanted or artificial) organs and the nervous system to increase the effective biointegration of these solutions. These “organ neuroprostheses” will become more and more valuable solutions in the years to come. The cover of article 2302896 by Silvestro Micera and co-workers show the possible use of nerve guidance channels to connect vagus nerve after heart transplantation. Cover design by Alessio Tommasetti.